NIAID Plans $20M for New Biodefense Countermeasures, Dx, Rx, Vaccines | GenomeWeb

NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Diseases plans to spend up to $20 million in fiscal year 2014 to fund efforts to develop lead candidates for diagnostics, therapeutics, and vaccines, that can be used as biodefense countermeasures against certain pathogens and toxins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.